Evidence for the Treatment of Osteoporosis with Vitamin D in Residential Care and in the Community Dwelling Elderly
Table 2
Characteristics of community studies.
Duration
Treatment
Dose (IU)
Regimen
Subjects
Female (%)
Age mean (SD) or median (range)
Vitamin D (nmol/L)# mean (SD) or median (IQR)
Ca+ intake (mg/day) mean (SD) or median (IQR)
RECORD
Median 45 months (range 24–62)
All
5292
85
77 (6)
NA
NA
D3
800 daily
D/CaD
2649
77 (6)
NA
NA
P
Ca/P
2643
77 (6)
NA
NA
Porthouse
Median 25 months (range 18–42)
All
3314
100
NA
D3
800 daily
CaD
1321
77 (5)
NA
1075 (338)
P
P
1993
77 (5)
NA
1084 (346)
WHI subgroup
7 years (mean)
All
6340
100
>70
NA
1150
D3
400 daily
CaD
3173
NA
NA
P
P
3167
NA
NA
Kyphos substudy
1 year
All
120
100
75 (3)
68 (29)
1010 (349)
D2
1000 daily
CaD
39
75 (3)
70 (26)
927 (295)
P
P CaP
41 40
75 (3) 74 (2)
67 (34) 67 (26)
1046 (340) 1054 (398)
Zhu
5 years
All
302
100
44 (13)
1097 (495)
D2
1000 daily
CaD
151
77 (4)
45 (13)
1109 (503)
P
CaP
151
77 (5)
44 (13)
1087 (410)
Lips-combined
3.5 years maximum
All
2578
74
80 (6)
NA
D3
400 daily
D
1291
80 (6)
27 19–36
NA
P
P
1287
80 (6)
26 19–37
NA
Heikinheimo community
2–5 years
All
479
77
NA
NA
D2
150000–300000 yearly*
D
199
87
NA
NA
P
P
280
86
NA
NA
Smith
3 years
All
9440
54
79 77–83
141 (59)
625 (231)
D2
300000 yearly*
D
4727
79 77–83
NA
NA
P
P
4713
79 77–83
NA
NA
IM treatment. #Divide by 2.5 for ng/mL. IU: international units; D2: ergocalciferol; D3: cholecalciferol; D: vitamin D only; CaD: calcium and vitamin D; Ca: calcium only; P: placebo or control; NA: not available.
